- Home
- SENEA vs ENGN Comparison
SENEA vs ENGN Comparison
Compare SENEA & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SENEA | ENGN |
|---|---|---|
| Founded | 1949 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Packaged Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 710.1M | 605.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SENEA | ENGN |
|---|---|---|
| Price | $116.87 | $11.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $22.71 |
| AVG Volume (30 Days) | 53.2K | ★ 399.3K |
| Earning Date | 02-05-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.79 | N/A |
| EPS | ★ 8.61 | N/A |
| Revenue | ★ $1,606,175,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.21 | ★ N/A |
| Revenue Growth | ★ 8.33 | N/A |
| 52 Week Low | $70.98 | $2.65 |
| 52 Week High | $129.03 | $12.25 |
Technical Indicators
Market Signals| Indicator | SENEA | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 56.91 | 67.87 |
| Support Level | $113.86 | $8.68 |
| Resistance Level | $119.85 | $12.25 |
| Average True Range (ATR) | 2.57 | 0.83 |
| MACD | 0.33 | 0.28 |
| Stochastic Oscillator | 70.71 | 78.90 |
Price Performance
Historical ComparisonAbout SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.